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ABSTRAK
Latar belakang: Tadalafil adalah sebuah PDE5I yang telah dilisensikan untuk menyembuhkan disfungsi ereksi 
sejak tahun 2003, efektif dari 30 menit setelah pemberian dan kemanjurannya dipertahankan hingga 36 jam. 
Baru-baru ini juga diberikan OAD dalam dosis yang lebih rendah untuk memungkinkan kegiatan seksual spontan. 
Namun, apakah pemberian OAD lebih efektif dibandingkan PRN dalam meningkatkan EF masih belum ditetapkan. 
Studi ini bertujuan untuk mengetahui apakah pemberian tadalafil sekali sehari lebih baik dalam meningkatkan 
fungsi ereksi pada pasien disfungsi ereksi (DE) dibandingkan pemberian on-demand/pro re nata (PRN). 
Metode: penelusuran dilakukan dengan menggunakan Medline, Scopus, Cochrane, dan CINAHL. Risiko bias pada 
tiap studi dinilai menggunakan Cochrane Risk of Bias Tool. Hasil: kami menemukan 231 studi dari penelusuran 
literatur, namun hanya empat studi yang sesuai kriteria seleksi. Berdasarkan penilaian kami, studi oleh Kang et 
al. merupakan yang paling sesuai dengan situasi klinis kami. Studi ini mendapatkan bahwa subyek yang mendapat 
tadalafil once a day (OAD) mengalami peningkatan yang lebih tinggi dan signifikan untuk skor IIEF-EF (6.5 (SB 
4.5) vs 4.9 (SB 4.2), p=0.032), proporsi “ya” terhadap SEP-2 (81.8% vs 64.7%, p=0.025), dan proporsi “ya” 
terhadap SEP-3 (77.3% vs 60.3%, p=0.034). Kesimpulan: pemberian tadalafil OAD akan memberikan peningkatan 
fungsi ereksi yang lebih baik dibandingkan dengan pemberian PRN.
Kata kunci: tadalafil, sekali sehari, disfungsi ereksi, IIEF.
ABSTRACT
Background: Tadalafil is a PDE5I which has been licensed for the treatment of erectile dysfunction (ED) 
since 2003, is effective from 30 minutes after administration and its efficacy is maintained for up to 36 hours. 
More recently, it is also given OAD in a lower dose to allow spontaneous sexual activities. However, whether OAD 
administration is more effective than PRN administration in improving the EF is yet to be established. This study 
aimed to evaluate whether OAD administration of tadalafil leads to a better improvement of erectile function (EF) 
in patients with erectile dysfunction (ED) compared to PRN administration. Methods: literature search of electronic 
database was performed through Medline, Scopus, Cochrane Library, and CINAHL databases. Cochrane Risk of 
Bias Tool was then employed to assess the risk of bias in each study. Results: initial literature search resulted in 
231 hits, but only four studies were included in final selection. Based on our judgements, the study by Kang et al. 
was the most applicable in our clinical setting. This study showed that subjects who received tadalafil OAD had 
statistically significant higher increases of mean IIEF-EF (6.5 (SD 4.5) vs 4.9 (SD 4.2), p=0.032), proportion of 
“yes” responses to SEP-2 (81.8% vs 64.7%, p=0.025), and proportion of “yes” responses to SEP-3 (77.3% vs 
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60.3%, p=0.034). Conclusion: administration of tadalafil OAD leads to a better improvement of EF compared 
to PRN administration.
Keywords: tadalafil, once-a-day, erectile dysfunction, IIEF.
INTRODUCTION
Erectile dysfunction (ED) is defined as 
the persistent inability to attain and maintain 
an erection sufficient for satisfactory sexual 
performance.1 According to the Massachusetts 
Male Aging Study (MMAS), one of the first 
epidemiology studies on ED involving a large 
number of subjects, the condition affects 52% 
of men between the ages of 40 and 70 years. 
Furthermore, by the age of 70, approximately 
68% of men reported to have ED, suggesting that 
ED is age-dependent.2 Nicolosi et al. reported 
the prevalence of sexual dysfunction in several 
Asian countries, including Indonesia. Based on 
their study, the prevalence of ED among adult 
Indonesian men was 11% (95% CI = 7-15).3 Several 
risk factors have been associated with ED. They 
include hypertension, diabetes, hyperlipidemia, 
and smoking.4 Furthermore, trauma to the pelvic 
region and radical prostatectomy have also been 
reported to cause ED.5,6
Treatment of ED starts from managing the 
modifiable risk factors and underlying conditions, 
which may involve lifestyle modifications. 
First-line therapy for ED is phosphodiesterase 
5 inhibitors (PDE5Is), e.g. sildenafil, tadalafil, 
and vardenafil. The differences between each 
PDE5I include the onset of action and duration 
of effect. To date, there is no guideline on which 
drug is more recommended for the treatment of 
ED. Patient’s choice and physician’s judgement 
must be considered when prescribing PDE5Is.1
Tadalafil, a PDE5I which has been licensed 
for the treatment of ED since 2003, is effective 
from 30 minutes after administration and its 
efficacy is maintained for up to 36 hours. It is 
administered PRN with doses of 10 mg and 20 
mg.7 More recently, it is also given OAD in a 
lower dose to allow spontaneous, rather than 
scheduled, sexual activities. However, whether 
OAD administration is more effective than PRN 
administration in improving the EF is yet to be 
established.
CASE ILLUSTRATION
A 61-year old sexually-active man came to 
a urologist, complaining of difficulty to achieve 
erection during sexual intercourse. On the 
occasions that he had an erection, he could not 
maintain penetration. Patient has been taking 
medications for hypertension and hyperlipidemia 
since 3 years ago. Patient did not have any history 
of surgery/trauma to the spine/pelvic region. 
When patient wanted to have sexual intercourse, 
he usually took tadalafil 20 mg, 30 minutes 
before the beginning of sexual intercourse. 
However, he felt it was rather inconvenient 
because he could not have spontaneous sexual 
intercourse with his sexual partner without 
taking tadalafil beforehand. The urologist read 
some publications stating that OAD, low-dose 
administration of tadalafil helps patients to have 
spontaneous sexual intercourse. The urologist 
wondered whether OAD administration of 
tadalafil is also more superior in improving EF 
compared to PRN administration in terms of 
efficacy and safety.
CLINICAL QUESTION
Does OAD administration of tadalafil lead to 
a better improvement of EF in patients with ED 
compared to PRN administration?
METHODS
Search Strategy
Literature search of electronic databases was 
performed in November 2017. We searched the 
literatures through Medline, Scopus, Cochrane 
Library, and CINAHL databases. The following 
key terms were used as MeSH and free text 
terms: “tadalafil”, “erectile dysfunction”, “on 
demand”, “as needed”, “pro re nata”, “once a 
day”, and “daily” (Table 1). Multiple synonyms 
of each term were also searched. All titles and 
abstracts retrieved by electronic search were 
screened for relevance and duplicates by two 
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reviewers (DTP and PARR). Following abstract 
screening, all full-text manuscripts of studies 
which did not undergo prior exclusion were 
reviewed for eligibility (Figure 1).
Eligibility Criteria
Studies which were included in this report 
fulfilled the following criteria: (1) study design 
was randomized control trial (RCT), systematic 
review, or meta-analysis; (2) subjects were at 
least 18 years of age and diagnosed with ED; (3) 
study evaluated the efficacy or safety of tadalafil 
OAD compared to PRN administration for ED. 
Studies were excluded if: (1) full text of 
English article was not available; (2) study did 
not measure EF using the International Index of 
Erectile Function-Erectile Function (IIEF-EF) 
or the Sexual Encounter Profile (SEP)-2 (“Were 
you able to insert your penis into your partner’s 
vagina?”) and SEP-3 (“Did your erection 
last long enough for you to have successful 
intercourse?”) scoring systems; (3) study was 
conducted in patients with prostate cancer; and 
(4) study was conducted in patients with history 
of surgery in the pelvic region.
Critical Appraisal
Critical appraisals of the included studies were 
performed by DTP and PARR, independently, 
using the RCT Critical Appraisal Sheet from 
the Centre for Evidence-Based Medicine. The 
Cochrane Risk of Bias Tool was then employed 
to assess the risk of bias in each study using 
seven domains: random sequence generation, 
allocation concealment, blinding of participants 
and personnel, blinding of outcome assessment, 
incomplete outcome data, selective reporting, 
and other source of bias. Authors’ judgments on 
the risks of bias for each study were divided into 
three categories: low risk, high risk, or unclear 
risk of bias (Figure 2).
Table 1. Keywords and search hits in Pubmed, Scopus, 
Cochrane Library, and CINAHL databases
Search 
Engine
Search Terms
Number 
of 
Articles
Pubmed
(“tadalafil” AND ("erectile 
dysfunction"[MeSH Terms] 
OR erectile dysfunction [Text 
Word]) AND (“on demand” OR 
“as needed” OR “pro re nata”) 
AND (“once a day” OR “daily”))
69
Scopus
TITLE-ABS-KEY ("tadalafil" 
AND "erectile dysfunction" AND 
("on demand" OR "as needed" 
OR "pro re nata") AND ("once a 
day" OR "daily"))
100
Cochrane 
Library
"tadalafil" AND "erectile 
dysfunction" AND ("on demand" 
OR "as needed" OR "pro re 
nata") AND ("once a day" 
OR "daily") in Title, Abstract, 
Keywords
54
CINAHL
“tadalafil” AND “erectile 
dysfunction” AND (“on demand” 
OR “as needed” OR “pro re 
nata”) AND (“once a day” OR 
“daily”)
8
* Searches were performed on November 10th, 2017
Figure 1. Flow chart of search strategy for study selection.
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RESULTS
Initial literature search using pre-determined 
terms in four search engines (Pubmed, Scopus, 
Cochrane Library, and CINAHL) resulted in 231 
hits. Duplicates screening excluded 128 articles, 
while title and abstract screenings excluded 
another 103 articles. Full-text articles for the 14 
titles not-excluded were assessed for eligibility, 
resulting in further 10 articles being excluded 
for final review due to: three articles were not in 
English, three articles did not use RCT design, 
one article used the same study subjects as one 
publication included in the critical appraisal, and 
three articles included subjects who did not meet 
the inclusion criteria of this study. The following 
four papers were included for final appraisal and 
assessment (Table 2).
Buvat et al.8 studied the effect of tadalafil 
OAD, tadalafil PRN, and sildenafil PRN towards 
several parameters including the IIEF-EF and 
SEP. The RCT involved 509 subjects with ED in 
a 24-week treatment period. Tadalafil OAD was 
given in a flexible dose adjustment between the 
2.5 mg and 5 mg preparations, while tadalafil 
PRN was given in a flexible dose adjustment 
between the 10 mg and 20 mg preparations. 
Although the improvement of EF was not the 
main outcome, this study included the changes 
of IIEF-EF and SEP from the baseline following 
treatment in the analysis. Both the tadalafil OAD 
and tadalafil PRN groups showed increases in 
mean IIEF-EF (9.4 (SD 7.0) vs 9.6 (SD 6.1), p 
>0.05) and proportion of “yes” responses to SEP-
3 (47.7% vs 49.9%, p >0.05). The differences, 
however, were not statistically significant.
In a 12-week RCT parallel study among 
168 ED subjects aged 20 years and above with/
without underlying diseases, Kang et al.9 studied 
the effect of tadalafil OAD 5 mg in 84 subjects 
and tadalafil PRN 20 mg in 84 subjects on EF 
as measured by IIEF-5 and SEP scores. Baseline 
characteristics of both groups were similar. Sixty-
six subjects who received tadalafil OAD and 68 
subjects who received tadalafil PRN completed 
the 12-week treatment period. Compared with 
subjects who received tadalafil PRN, subjects 
who received tadalafil OAD showed statistically 
significant higher increases of mean IIEF-EF (6.5 
(SD 4.5) vs 4.9 (SD 4.2), p = 0.032), proportion 
of “yes” responses to SEP-2 (81.8% vs 64.7%, 
p = 0.025), and proportion of “yes” responses to 
SEP-3 (77.3% vs 60.3%, p = 0.034).
McMahon et al.10 conducted an RCT 
crossover study among 145 patients with ED 
over a 12-week treatment period comparing 
tadalafil OAD (10 mg) with tadalafil PRN (20 
mg). Compared with baseline, tadalafil OAD 
and PRN enhanced all efficacy outcomes (IIEF-
EF, SEP). Subjects receiving tadalafil OAD 
experienced a higher increase of mean IIE-EF 
score compared to subjects receiving tadalafil 
PRN (11.9 vs 8.3, p = 0.001). Likewise, SEP-2 
and SEP-3 scores also experienced gains in the 
mean scores following treatment with tadalafil, 
with the OAD regimen having higher increases 
compared with the PRN regimen (SEP-2 85% 
vs 73%, p <0.05; SEP-3 80% vs 67%, p <0.05). 
The last study which was assessed in this 
report is the study by Rubio-Aurioles et al.11 
The study involved men at least 18 years of age 
with history of ED and satisfactory response to 
current oral PDE5I PRN. Three hundred and 
seventy-eight subjects were divided into six 
groups which received, alternatingly, tadalafil 
Figure 2. Authors’ judgements on each risk of bias item for 
appraised studies.
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OAD 5 mg, tadalafil PRN 20 mg, and sildenafil 
PRN 100 mg for 8 weeks. EF was measured 
by IIEF-EF only. Similar to other literatures 
included in this report, the study showed that 
subjects who received tadalafil OAD had a 
higher mean IIEF-EF increase compared to those 
who received tadalafil PRN, despite not being 
statistically significant (8.7 (SD 6.7) vs 9.5 (SD 
6.8), p = 0.092).
Based on our judgements, the study by 
Kang et al.9 is the most applicable in our clinical 
setting. The patients’ characteristics were similar 
to our patients and they used the same parameter 
to assess the EF by using the much simpler, IIEF-
5 questionnaire. However, as with most clinical 
trials evaluating the effect of PDE5Is towards 
EF, there were high risks of performance and 
detection biases due to the absences of participant 
279
Dimas T. Prasetyo                                                                                                                       Acta Med Indones-Indones J Intern Med
and outcome assessment blinding.
Some of the studies also compared the safety 
of tadalafil OAD to PRN. Buvat et al.8 reported 
10/257 (3.9%) and 7/252 (2.8%) patients from 
the OAD and PRN groups experienced adverse 
events, respectively (p = 0.623). However, no 
detail was listed regarding the adverse events. 
Kang et al.9 reported 6/84 (7.1%) patients who 
received tadalafil OAD and 7/84 (8.3%) patients 
who received tadalafil PRN experienced adverse 
events with the difference being not statistically 
significant. Facial flushing was the most common 
adverse events (OAD group: n = 4; PRN group: 
n = 4), followed by headache (OAD group: n = 
2; PRN group: n = 2), and dizziness (PRN group: 
n = 1). Both articles did not report any serious 
adverse event caused by both tadalafil OAD and 
PRN during study period.
DISCUSSION
Tadalafil is a selective PDE5I with a half-life 
of 17.5 h, which is longer than other available 
PDE5Is. This proves to be an advantage to 
men taking tadalafil by providing a wide range 
of possibilities in which to engage in sexual 
intercourse. The launch of low-dose tadalafil 
OAD, which can maintain a pharmacodynamic 
plasma concentration of 55 ng/mL throughout 
the 24-hour dosing interval12, enables men taking 
it to have spontaneous sexual intercourse in 
contrast to scheduled sexual intercourse when 
taking the PRN dosage.13
The inconvenience caused by scheduled 
sexual intercourse when taking tadalafil PRN 
may also have psychological implications for 
patients. These psychological factors could 
affect patients’ sexual intercourse performance, 
confidence, and quality of life. Tadalafil’s half-life 
could be an important changing factor regarding 
this concern. In theory, a much longer effective 
plasma concentration could be maintained 
with an OAD administration compared to PRN 
regimen, thus allowing patients to feel ready for 
sexual intercourse at any time and enabling them 
to separate the stigma of drug intake from the act 
of sexual intercourse.
We studied whether tadalafi l  OAD 
administration in patients with ED resulted in 
better improvement of EF compared to tadalafil 
PRN. Our extensive search retrieved four 
RCTs which fulfilled our eligibility criteria for 
this report. All four studies reported increased 
IIEF-EF and IIEF-5 scores as well as higher 
proportion of “yes” responses to SEP-2 and 
SEP-3 following treatment with PDE5Is with 
most of them showing higher gains of IIEF-EF 
and IIEF-5 scores as well as higher proportion 
increase of “yes” responses to SEP-2 and SEP-3 
in patients who received tadalafil OAD compared 
to tadalafil PRN.
In general, there was no significant difference 
between tadalafil OAD compared to tadalafil 
PRN in term of incidence of adverse effects. 
Regardless of which dosing regimen was used, 
the adverse effects were relatively rare and 
well tolerated. However, several studies found 
that tadalafil OAD had a lower incidence of 
headache and flushing compared to the tadalafil 
PRN dosing. One possible explanation is that 
headache and flushing are more likely to be 
associated with peak drug plasma concentration, 
which is much higher in tadalafil PRN compared 
with tadalafil OAD dosing.13
CONCLUSION
Administration of tadalafil OAD for 
the management of ED provides not only 
the possibility to have spontaneous sexual 
intercourse to the users, but also leads to 
better improvement of EF compared to PRN 
administration. However, patient’s preference 
and physician’s judgment are still the most 
important considerations when deciding to give 
PDE5I to patients with ED.
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